Request for Information (RFI): Comments to Advance and Strengthen Racial Equity, Diversity, and Inclusion in the Biomedical Research Workforce and Advance Health Disparities and Health Equity Research

This RFI will assist NIH in identifying, developing, and implementing strategies that will allow the biomedical enterprise to benefit from a more diverse and inclusive research workforce and a more robust portfolio of research to better understand and address inequities in our existing system.

Notice: To add harassment as an area of interest to Research to Understand and Inform Interventions that Promote the Research Careers of Individuals in the Biomedical Sciences

Summary: The purpose of this Notice is to inform potential applicants of the NIH’s interest in supporting research on interventions designed to change the culture to mitigate or eliminate sexual harassment in the biomedical research enterprise. This notice aligns with the Anti-Sexual Harassment policy statements released by NIH as well as recommendations made in the December 2019 Report from the Working Group to the Advisory Committee to the NIH Director (ACD) on Changing the Culture to End Sexual Harassment, which were endorsed by the ACD.

Proposal Due Date: October 15, 2021

NIH Notice: Announcement of Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellows

Summary: NIH recognizes that the high cost of childcare impacts graduate students and post-doctorates funded through NRSA fellowships, and their ability to successfully complete their training and fully participate in the extramural research workforce. Therefore, as part of our ongoing efforts to support family-friendly work environments for the NIH-supported workforce, NIH will begin providing childcare support to recipients of NRSA fellowships, on or after April 8, 2021. In Phase 2 of this initiative, a similar cost will be provided for NRSA-supported trainees (anticipated early FY 2022). For Phase 2 of this initiative, additional information and implementation guidance will be issued.

NIH/National Institute of General Medical Sciences Notice: Urgent Competitive Revisions to IDeA and NARCH Programs to Address SARS-CoV-2 Vaccine Hesitancy

A significant number of Americans, especially those in medically underserved communities, have doubts about vaccination. The goal of this NOSI is to support IDeA and NARCH grantees to conduct research that helps understand the causes of vaccine hesitancy and/or tests intervention strategies to increase vaccine uptake in IDeA states and/or the American Indian/Alaska Native (AI/AN) communities.

Expiration date: May 1, 2021

Triadic Interactions in Clinical Encounters Involving People with Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners

Summary: The goal of this initiative is to support research that can lead to the development of interventions for optimizing communications among patients, caregivers, and health care practitioners, and for preserving strong and supportive caregiving relationships throughout disease progression along the continuum of care for people with AD/ADRD. Priority areas include effective communications and relationships among patients, healthcare practitioners and caregivers; and associations between close relationship processes and health in caregiving relationships.

Proposal Due Date: June 23, 2021

The Midlife in the United States Study—Cognitive and Neurocognitive Precursors of AD/ADRD

Proposal Due Date: November 18, 2021

Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and Other Cargoes for HIV and SUD Mechanistic or Therapeutic Research

Summary: The purpose of this funding opportunity is to develop technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and SUD mechanistic research.

Proposal Due Date: October 25, 2022

National Institutes of Health, Research on Bat Immunology (R21Clinical Trial Not Allowed)

Summary: To support research to characterize cellular and molecular constituents of the bat immune system and to understand protective innate and adaptive immune mechanisms in bats.

Proposal Due Date: July 15, 2021
                                                                                                                       

Notice of Special Interest (NOSI): Tailoring Follow-up Care for Survivors Using Risk-Stratified Pathways
(NOT-CA-21-019) National Cancer Institute

The purpose of this Notice is to highlight the NCI Division of Cancer Control and Population Sciences’ interest in receiving applications focused on identifying important factors for defining risk-stratified survivorship care or developing and testing approaches to improve the clinical management and outcomes for adult cancer survivors using risk-stratified survivorship care pathways.  Applicants are encouraged to discuss their application with the scientific/research contacts listed in this notice prior to submission. This notice applies to standard due dates on or after February 5, 2021 and subsequent receipt dates through February 5, 2023. 

Mentored Research Experiences for Genetic Counselors (R25)
(PAR-21-074) National Human Genome Research Institute

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this NHGRI R25 program is to help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. Application Receipt Date(s): May 25, 2021, May 25, 2022, and May 25, 2023.

Research Experiences in Genomic Research for Data Scientists (R25)
(PAR-21-075) National Human Genome Research Institute

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this NHGRI R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. Application Receipt Date(s): May 25, 2021; May 25, 2022; May 25, 2023.

NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 No Independent Clinical Trials)
(PAR-21-086) National Institute on Deafness and Other Communication Disorders
The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Application Receipt Date(s):  June 17, 2021; October 13, 2021; February 17, 2022; June 14, 2022; October 13, 2022; February 14, 2023; June 13, 2023; October 13, 2023.

NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)
(PAR-21-087) National Institute on Deafness and Other Communication Disorders
The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. Application Receipt Date(s): June 17, 2021; October 13, 2021; February 17, 2022; June 14, 2022; October 13, 2022; February 14, 2023; June 13, 2023; October 13, 2023.

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)
(PAR-21-097) National Institute on Alcohol Abuse and Alcoholism
This Funding Opportunity Announcement (FOA) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. Application Receipt Date(s): June 17, 2021, October 19, 2021, February 17, 2022, June, 17, 2022, October 18, 2022, February 17, 2023, June 19, 2023, October 17, 2023

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
(PAR-21-098) National Institute on Alcohol Abuse and Alcoholism
This Funding Opportunity Announcement (FOA) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase.  Application Receipt Date(s): June 17, 2021, October 19, 2021, February 17, 2022, June, 17, 2022, October 18, 2022, February 17, 2023, June 19, 2023, October 17, 2023.

Aging Effects on Osteoimmunology (R01 Clinical Trials Not Allowed)
(RFA-AG-22-002) National Institute on Aging
This Funding Opportunity Announcement (FOA), issued by the National Institute on Aging (NIA) of the National Institutes of Health, solicits grant applications that will examine the role of aging in the interactions between the immune systems and skeletal systems in animal models. Research projects that will determine the mechanisms involved in how both aging of the bone marrow niche and immunosenescence impact these interactions, leading to pathological conditions in bone homeostasis, are the focus of this FOA. Application Receipt Date(s): June 15, 2021. 

NIAMS Centers of Research Translation (CORT) (P50 - Clinical Trial Not Allowed)
(RFA-AR-22-001) National Institute of Arthritis and Musculoskeletal and Skin Diseases
This Funding Opportunity Announcement (FOA) invites applications for Centers of Research Translation (CORT). Overall, a CORT research program should be carried out by a synergistic team of scientists who, through an interdisciplinary team science approach, will address a highly significant translational research challenge in a single or a group of highly-related disease(s) or condition(s) within the mission of the NIAMS. The focus of research could be either 1) a disease-targeted translational theme addressed by synergistic Research Projects with optional Research Cores; or 2) a disease-related critical translational research question addressed through a single collaborative Research Project enabled by a number of highly interactive Research Cores whose work is integrated during the development and implementation of the Project. Application Receipt Date(s): May 11, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

New Chemistries for Un-drugged Targets through A Specialized Platform for Innovative Research Exploration (ASPIRE) Collaborative Research Program (UG3/UH3 Clinical Trials Not Allowed)
(RFA-TR-21-001) National Center for Advancing Translational Sciences
The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop approaches that will enhance the ability to discover and develop new chemistries towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. Application Receipt Date(s): July 8, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Virtual Approaches Towards New Chemistries for Un-drugged Targets through A Specialized Platform for Innovative Research Exploration (ASPIRE) Collaborative Research Program (U18 Clinical Trials Not Allowed)
(RFA-TR-21-002) National Center for Advancing Translational Sciences
The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop approaches that will enhance our ability to discover and develop new chemistries designed towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. Application Receipt Date(s): July 8, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)
(RFA-CA-21-003) National Cancer Institute

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Application Receipt Date(s): May 27, 2021; September 29, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
(RFA-CA-21-004) National Cancer Institute
This Funding Opportunity Announcement (FOA) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Application Receipt Date(s): May 27, 2021; September 29, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)
(PAR-21-022)

The purpose of this FOA is to support the development and testing of implementation strategies to achieve system-level adoption of evidence-based interventions, guidelines, or practices to improve the delivery, quality, and sustainability of prevention or treatment services for substance use disorders. Application Receipt Date(s): July 19, 2021; November 15, 2021; July 19, 2022; November 15, 2022; July 19, 2023; November 15, 2023.

Diabetes Research Centers (P30 Clinical Trial Optional)
(RFA-DK-20-025) National Institute of Diabetes and Digestive and Kidney Diseases
This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases.  Diabetes Research Centers support two primary research-related activities:  Research Core services and a Pilot and Feasibility (P and F) program. Application Receipt Date(s): May 20, 2021

Notice of Special Interest: Advances in Research for the Treatment, Services, and Recovery of Alcohol Use Disorder
(NOT-AA-20-022) National Institute on Alcohol Abuse and Alcoholism

The purpose of this Notice of Special Interest (NOSI) is to advance research on various topics that fall within NIAAA’s Division of Treatment and Recovery Research (DTRR). DTRR’s research interests are wide-ranging and encompass broad categories such as health services, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for alcohol use disorder (AUD) treatment and sustaining recovery. This notice applies to standard due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2023. 

Notice of Special Interest: Kidney Precision Medicine Technology Development and Translation
(NOT-DK-21-007) National Institute of Diabetes and Digestive and Kidney Diseases

This NOSI intends to encourage small businesses to translate kidney precision medicine discoveries and technologies. This notice applies to due dates on or after January 5, 2021 and subsequent receipt dates through September 5, 2023. 

Notice of Special Interest (NOSI): High-throughput Molecular and Cellular Phenotyping
(NOT-HG-21-004) National Human Genome Research Institute

The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel methods to perform high-throughput molecular and cellular phenotyping in order to elucidate the functional consequences of DNA variation. This notice applies to due dates on or after February 5, 2021 and subsequent receipt dates of current and reissued FOAs through January 10, 2024.

NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional)
(PAR-21-073) National Eye Institute
The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions to propose creative and innovative institutional research career development programs which prepare clinically trained vision scientists for independent research careers.  This initiative is intended to expand and strengthen the community of clinician investigators engaged in clinical research. Application Receipt Date(s): June 9, 2021; June 9, 2022; June 9, 2023.

NHLBI Program Project Applications (P01 Clinical Trials Optional)
(PAR-21-088) National Heart, Lung, and Blood Institute
This Funding Opportunity Announcement (FOA), issued by the National Heart, Lung, and Blood Institute (NHLBI) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also include implementation science, health disparities, and translation research that addresses the mission of the Institute. Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is January 25, 2021 and subsequent receipt dates through September 26, 2023.

Limited Competition: Small Grant Program for ORIP Special Emphasis Research Career Award (SERCA) K01 Recipients (R03 Clinical Trials Not Allowed)
(PAR-21-090) Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
The Office of Research Infrastructure Programs (ORIP) within the Division of Program Coordination, Planning, and Strategic Initiatives announces an opportunity to apply for small grant support for ORIP-supported Special Emphasis Research Career Award (SERCA) K01 recipients who have completed the first two years (24 months) of the SERCA K01 award. Application Receipt Date(s): February 16, 2022; and February 16, 2023.  *Please note that institutional policies regarding limited submission opportunities must be followed if considering this funding mechanism.

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
(RFA-CA-21-013) National Cancer Institute
The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. Application Receipt Date(s): June 8, 2021; November 17, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
(RFA-CA-21-014) National Cancer Institute
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. Application Receipt Date(s): June 8, 2021; November 17, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)
(RFA-CA-21-017) National Cancer Institute
The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. Application Receipt Date(s): June 08, 2021; November 17, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)
(RFA-CA-21-018) National Cancer Institute
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. Application Receipt Date(s): June 08, 2021; November 17, 2021 No late applications will be accepted for this Funding Opportunity Announcement.

Notice of Intent to Publish a Funding Opportunity Announcement for Ocular Surface Innervation from Cell Types to Circuit Functions (U01 Clinical Trial Not Allowed)
(NOT-EY-21-005) National Eye Institute

The NEI intends to promote a new initiative by publishing a Request for Applications (RFA) to solicit applications for research that will cooperatively and comprehensively dissect ocular surface innervation – from corneal sensation to pain circuits and tearing reflexes. This RFA aims to explore this system at three levels of analysis: morphologic, molecular, and functional. The FOA is expected to be published in February 2021 with an expected application due date in June 2021.

Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications
(NOT-EB-20-017)

The overarching goal(s) of this Notice are to: develop tools and technologies to control and reprogram biological systems; apply synthetic biology approaches for the development of biomedical technologies; increase the fundamental understanding of synthetic biology concepts as they relate to human health, and gain fundamental biological knowledge through the application of synthetic biology approaches.  This notice applies to due dates on or after January 19, 2021 and subsequent receipt dates through January 18, 2024.  Please see related funding opportunity announcements within each institute’s notice to determine exact due dates.

Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
(PAR-21-068)
This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Only accepting applications for the AIDS standard Application Due Date(s). The first AIDS application due date for this FOA is May 7, 2021 and subsequent receipt dates through January 8, 2024.

Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
(PAR-21-069)

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Standard AIDS dates apply. The first AIDS application due date for this FOA is May 7, 2021 and subsequent receipt dates through January 8, 2024.

NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)
(PAR-21-084) National Institute of Dental and Craniofacial Research
This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator­ initiated Research Project Grant (R01) or equivalent application. Application Receipt Date(s): Standard due dates apply. The first standard due date for this FOA is February 16, 2021 2021 and subsequent receipt dates through January 8, 2024.

Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
(RFA-CA-21-007) National Cancer Institute
The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. Application Receipt Date(s): May 27, 2021; September 29, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
(RFA-CA-21-008) National Cancer Institute
The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. Application Receipt Date(s): May 27, 2021; September 29, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)
(RFA-CA-21-011) National Cancer Institute
The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications from currently funded NCI P01 program projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. Application Receipt Date(s): Sept 29, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)
(NOT-HL-20-823) National Heart, Lung, and Blood Institute

Grants funded under this initiative will have access to data via dbGaP, including phenotype and genotype data, transcriptomics, methylation, metabolomics, and harmonized phenotypes produced by the TOPMed Data Coordinating Center (DCC) and jointly called sequence data generated by the TOPMed Informatics Research Center (IRC). Applicants are also encouraged to utilize emerging NHLBI cloud resources as they become available. This notice applies to standard due dates on February 5, 2021 and subsequent receipt dates through May 8, 2023.  

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
(PA-21-071)

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (see notice for activity codes) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. Application Receipt Date(s): Due dates vary by awarding IC with receipt dates through May 8, 2023.

Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)
(PAR-21-056) National Institute of Neurological Disorders and Stroke
This PAR is intended to address the gap in biomarker validation by encouraging rigorous analytical validation of the biomarker detection method. Applications to this PAR must propose to conduct analytical validation of a biomarker or biomarker signature that already has a well-defined proof of concept and biological rationale. Premise and proof of concept must include evidence that the biomarker/biomarker signature has been tested in an appropriate clinical population, using either prospective or retrospective data or samples and shows sufficient sensitivity and specificity to warrant additional investment. Application Receipt Date(s):  June 22, 2021, February 22, 2022, June 22, 2022, February 22, 2023, and June 22, 2023.

Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)
(PAR-21-065) National Cancer Institute
To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.  Application Receipt Date(s): Standard due dates apply. The first standard due date for this FOA is January 25, 2021 and subsequent receipt dates through January 8, 2024.  

Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)
(PAR-21-066) National Cancer Institute
To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission. Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is January 25, 2021 and subsequent receipt dates through January 8, 2024.  

Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)
(PAR-21-067) National Cancer Institute
To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on  Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission. Application Receipt Date(s): Standard due dates apply. The first standard due date for this FOA is January 25, 2021 and subsequent receipt dates through January 8, 2024.  

Biological Testing Facility (X01 Clinical Trial Not Allowed)
(PAR-21-078) Eunice Kennedy Shriver National Institute of Child Health and Human Development
The purpose of this FOA is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program. This FOA aims to position innovative and validated methods for future clinical development. Application Receipt Date(s): July 15, 2021, January 14, 2022, July 15, 2022.

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01 Clinical trial not allowed)
(PAR-21-080)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations. Standard due dates apply. The first standard due date for this FOA is January 5, 2021 and subsequent receipt dates through January 8, 2023.  

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)
(RFA-CA-21-005) National Cancer Institute
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. Application Receipt Date(s): May 27, 2021; September 29, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Outstanding New Environmental Scientist (ONES) Award (R01 Clinical Trial Optional)
(RFA-ES-21-001) National Institute of Environmental Health Sciences
The Outstanding New Environmental Scientist (ONES) Award is intended to identify the most talented Early Stage Investigators (ESIs) who intend to make a long-term commitment to research in the Environmental Health Sciences and assist them in launching an innovative research program focused on understanding the effects of environmental exposure on people’s health. Application Receipt Date(s): February 24, 2022; February 24, 2023.

Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed)The NIH and NCI offer this funding opportunity to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.  The overarching objective of this Funding Opportunity (FOA)is to enhance population-based research on liver cancer in the United States(U.S.). Specifically, this liver cancer FOA seeks to support epidemiologic research to expand our understanding of the etiology of the malignancy, including expanding investigations on unanswered questions related to viral hepatitis-associated liver cancer, and exploring emerging and novel riskfactors that may contribute to the rising burden of liver cancer in the U.S. The funded projects will contribute to the body of evidence needed to inform evidence-based prevention and control strategies of liver cancer. While hepatocellular carcinoma (HCC; ICD10 code C22.0) accounts for approximately85-90% of all primary liver cancer, this FOA will also include support of applications seeking to better understand the etiology of other histological subtypes such as cholangiocarcinoma, hepatoblastoma, and angiosarcoma of liver. These subtypes are rare but add to the burden of primary liver cancer and have been under-investigated.  Application due:  June 5, 2021, and October 5, 2021. 

Notice of Special Interest (NOSI): Administrative Supplement for Providing Travel Support for Awardees to Attend the Annual NIH Synthetic Biology Consortium Meeting (Admin Supp)
(NOT-EB-20-022) National Institute of Biomedical Imaging and Bioengineering

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) announces the availability of Administrative Supplements to provide travel support for awardees of the Synthetic Biology for Biomedical Applications Notice (NOT-EB-20-017) to attend the annual NIH Synthetic Biology Consortium Meeting (eligible applicants are those who have received an award made in response to NOT-EB-20-017). This notice applies to standard due dates on or after January 19, 2021 and subsequent receipt dates through January 18, 2024.

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Humans Required)
(PAR-21-039)

This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies that are NOT conducted with specific applications toward processes or products in mind and which also do not meet the clinical trial definition should submit under the appropriate ‘Clinical Trial Not Allowed’ FOA. Application Receipt Date(s): May 26, 2021; September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023.

Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
(PAR-21-053) National Institute of Arthritis and Musculoskeletal and Skin Diseases
This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. A future clinical study may include a clinical trial or an observational study. Research data from observational studies supported by this FOA can enhance clinical study design by providing essential information about disease symptoms, stages, and timing of disease progression; comorbid conditions; availability of potential research participants; and outcomes that are important to patients. They also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in a future clinical study. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, such as determining the appropriate primary or secondary outcome measures or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA. Application Receipt Date(s): July 2, 2021, November 2, 2021 March 4, 2022, July 1, 2022, November 4, 2022 March 3, 2023, July 2, 2023, November 3, 2023.

Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)
(PAR-21-070)

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative, interdisciplinary early-stage research to inform the development of innovative rapid, sensitive, simple, and cost-effective diagnostic technologies that will enable HIV self-testing during the earliest phases of acute infection or during viral rebound. Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed here. March 17, 2022; March 17, 2023.

NIAAA Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
(PAR-21-072) National Institute on Alcohol Abuse and Alcoholism
The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field.  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is January 25, 2021 and subsequent receipt dates through September 26, 2023.

Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed)
(PAR-21-077) National Institute of General Medical Sciences
The purpose of this funding opportunity announcement (FOA) is to support efficient collection, banking, and sharing of biospecimens and associated clinical data from critically ill patients, ultimately for use in mechanistic research on sepsis. The goals of this FOA are to determine the scientific value of existing or newly collected sepsis human biospecimen sets as testbeds for studies on human sepsis and to provide guidance on the best practices for collecting, utilizing, and analyzing human biospecimens, thus maximizing their value for the entire sepsis research community. Application Receipt Date(s): November 16, 2022.

Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R01 Clinical Trial Optional)
(RFA-MH-21-110) National Institute of Mental Health
NIMH seeks applications for research projects to evaluate the effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Application Receipt Date(s): October 15, 2021; June 15, 2022.

Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 Clinical Trial Optional)
(RFA-MH-21-111) National Institute of Mental Health
 NIMH seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Application Receipt Date(s): October 15, 2021; June 15, 2022.

Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R43/R44 Clinical Trial Optional)
(RFA-MH-21-112) National Institute of Mental Health
This SBIR Funding Opportunity Announcement (FOA) is intended to support small businesses to develop and test service-ready, commercially viable tools and technologies for suicide prevention, including technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Application Receipt Date(s): October 15, 2021, June 15, 2022

Notice of Special Interest (NOSI): Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data
(NOT-CA-21-008) National Cancer Institute

Applications are invited, through PA-20-272 in conjunction with this Notice of Special Interest (NOSI), for one-year administrative supplements to support the adaptation and repackaging of existing broad-based visualization methods that have the potential to make Cancer Moonshot-aligned data more explorable and interpretable by the broader cancer research community. Applications will be accepted starting December 2, 2020. Applications can be submitted on a rolling basis for possible funding in FY2021, FY2022, and FY2023. This NOSI will expire on November 3, 2022. However, continuation of this NOSI is contingent upon availability of funds.

Limited Competition: Lasker Clinical Research Scholars Transition Award (R00 Clinical Trial Optional)
(PAR-20-315)
The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers.  This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program.  In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility. Application Receipt Date(s): Rolling receipt dates: May 31, 2021; June 1, 2021 September 30, 2021; October 1, 2021 January 31, 2022; February 1, 2022 May 31, 2022; June 1, 2022 September 30, 2022; October 1, 2022- January 31, 2023; February 1, 2023 - May 31, 2023; June 1, 2023 September 30, 2023.

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
(PAR-21-038)

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Application Receipt Date(s): May 26, 2021; September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023.

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)  Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning research project grant applications that (1) identify a baseline rate of DUP in community or institutional settings; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP. Alternatively, applicants who have already completed significant developmental or pilot work in this area are encouraged to apply to the companion R01 FOA PAR-19-236Application due: June 16, 2021, and October 16, 2021. 

Notice of Special Interest: Competitive Supplements for Implementation Science Research as Part of NHLBI-funded Phased Awards (R61/R33 and UG3/UH3)
(NOT-HL-20-795) National Heart, Lung, and Blood Institute

This NOSI aims to incorporate an implementation research question into Phase II and III NHLBI clinical trials that are part of phased awards (R61/R33 and UG3/UH3). The purpose of this NOSI is to strengthen the impact of findings from the parent study and prepare for ready uptake of the clinical study results into practice and real-world applications. The parent activity code of the existing award must be an NHLBI-funded R61/R33 or UG3/UH3 phased award. Applications in response to this Notice must be submitted through PA-20-163, Competing Revisions to Existing NIH Grants and Cooperative Agreements (Clinical Trial Optional). Applications for revisions in response to this Notice must follow application instructions and be submitted on the following dates: November 23, 2021; and November 23, 2022.

Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders
(NOT-HL-20-815) National Heart, Lung, and Blood Institute

NHLBI is issuing this Notice of Special Interest (NOSI) to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions. The first available due date is February 5, 2021 and subsequent receipt dates through September 8, 2022. 

Submit applications for this NOSI using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

  • PAR-19-274 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
  • PA-20-185  - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)
(PA-21-048)

The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers.  Applications are expected to incorporate exceptional mentorship. Standard due dates apply.  The first available due date is December 8, 2020 and subsequent receipt dates through September 8, 2023. 

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
(PA-21-050)

This Funding Opportunity Announcement (FOA) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. Standard due dates apply.  The first available due date is December 8, 2020 and subsequent receipt dates through September 8, 2023. 

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)
(PA-21-052)

The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce. Through this award program, promising predoctoral students will obtain individualized, mentored research training from outstanding faculty sponsors while conducting well-defined research projects in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. Standard due dates apply.  The first available due date is December 8, 2020 and subsequent receipt dates through September 8, 2023. 

Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists (R25 Clinical Trials Not Allowed)
(PAR-20-236) National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research Application Receipt Date(s): August 10, 2021, November 15, 2021, March 15, 2022, August 10, 2022, November 15, 2022 , March 15, 2023, August 10, 2023, November 15, 2023.

NINDS Research Education Programs for Residents and Fellows in Neurological Disorders and Stroke (R25 - Clinical Trial Not Allowed)
(PAR-20-311) National Institute of Neurological Disorders and Stroke
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.Application Receipt Date(s): January 25, 2023.

Notice of Special Interest (NOSI): Development and/or Validation of Devices or Electronic Systems to Monitor or Enhance Mind and Body Interventions (SBIR/STTR)
(NOT-AT-21-001) National Center for Complementary and Integrative Health

The National Center for Complementary and Integrative Health (NCCIH) is committed to the rigorous investigation of mind and body interventions (MBIs) to determine their usefulness and safety. Through this Notice of Special Interest (NOSI), NCCIH supports cutting-edge Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications from small business concerns that will develop and/or validate devices or electronic systems that can: 1) monitor biologically or behaviorally based processes applicable to MBIs or 2) be used in optimizing the practice or increasing the efficacy of MBIs. This notice applies to due dates on or after January 05, 2021 and subsequent receipt dates through January 05, 2024. 

Notice of Special Interest: Administrative Supplements to Support Dentist Scientists Post Specialty or Residency to Develop Expertise in Dental, Oral and Craniofacial Research
(NOT-DE-20-035) National Institute of Dental and Craniofacial Research

The purpose of the NIDCR Dentist Scientist Administrative Supplement Program is to enhance the research careers of dentist-scientists who can contribute vital clinical perspectives to dental, oral and craniofacial research projects, and to build and sustain a dentist-scientist research workforce dedicated to improving dental, oral and craniofacial health. The program will provide supplemental funds to active NIDCR research grants to support mentored research experiences for outstanding early career dentist-scientists who have recently completed dental specialty or residency training. The program is intended to accelerate the candidate’s transition from primarily clinical activities to predominantly research activities by providing protected time to develop or update research skills, formulate a research career plan, generate preliminary data and seek independent funding. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

  • PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

NIDCR accepts and reviews administrative supplement applications on a continuous basis during the fiscal year (October 1 – September 30). However, applications must be submitted by 5 pm local time of the grantee institution on July 14 to be considered for funding before the end of fiscal year in 2021 and 2022.

Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
(NOT-NS-20-107)

This notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-20-222 (or any subsequent reissuances), Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). This notice is part of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is a trans-NIH effort to (1) improve prevention and treatment strategies for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://heal.nih.gov/. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent:

  • PA-20-222 - Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Application Due Date(s) – November 15, 2020, February 15, 2021, May 15, 2021, November 15, 2021, February 15, 2022, May 15, 2022, November 15, 2022, February 15, 2023, May 15, 2023, November 15, 2023, February 15, 2024, and May 15, 2024.

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)
(PA-21-047)

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers.  Application Receipt Date(s): Standard dates apply. First available due date: December 8, 2020 and subsequent receipt dates through September, 8 2023. 

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)
(PA-21-051)

The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the candidate’s dissertation research project and is expected to clearly enhance the individual’s potential to develop into a productive, independent research scientist. Application Receipt Date(s): Standard dates apply. First available due date: December 8, 2020 and subsequent receipt dates through September, 8 2023. 

NIDDK Education Program Grants (R25 Clinical Trial Not Allowed)
(PAR-21-034) National Institute of Diabetes and Digestive and Kidney Diseases

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development and Research Experiences. These courses for skill development and research experiences must fall within NIDDK's mission areas. NIDDK supports research training skill development and research experiences on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases. Application Receipt Date(s): January 28, 2021; January 28, 2022; January 31, 2023.

Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
(PAR-21-054) National Institute of Arthritis and Musculoskeletal and Skin Diseases

This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects (parent projects). The parent projects can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The parent project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Application Receipt Date(s): March 18, 2021; July 20, 2021; November 18, 2021; March 18, 2022; July 20, 2022; November 18, 2022.

Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
(PAR-21-055) National Institute of Arthritis and Musculoskeletal and Skin Diseases

This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects (parent projects). The parent projects can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The parent project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Application Receipt Date(s): March 18, 2021; July 20, 2021; November 18, 2021; March 18, 2022; July 20, 2022; November 18, 2022.

NIDDK Research Education Program Utilizing Stimulating Peripheral Activity to Relieve Conditions (SPARC) - Generated Resources (R25 Clinical Trial Not Allowed)
(RFA-DK-20-020) National Institute of Diabetes and Digestive and Kidney Diseases

This Funding Opportunity Announcement (FOA) invites applications to establish research programs for qualified graduate students, post-doctoral fellows, medical residents, biomedical engineers, and clinical fellows to engage in neuroscience research experiences relevant to the mission of NIDDK and its partnership with the Common Fund program, Stimulating Peripheral Activity to Relieve Conditions (SPARC). The intent is to leverage this partnership to provide resources for short-term research experiences that would necessarily use SPARC-generated resources (datasets/maps/models) as the foundation for the research experience in conjunction with educational activities that may be combined with hands-on computational or ‘wet lab’ projects. Application Receipt Date(s): November 9, 2021, and November 9, 2022.  Letter of Intent Due Dates: October 9, 2021, and October 9, 2022.

Notice Announcing Availability of Data Harmonization Tools for Social Determinants of Health (SDOH) via the PhenX Toolkit

(NOT-MD-21-003)

The purpose of this Notice is to announce a major data-harmonization effort at the National Institute on Minority Health and Health Disparities (NIMHD) and to encourage the minority health and health disparities research community to use new data collection tools emerging from this effort. The NIMHD is dedicated to advancing science by improving the yield and impact of its research portfolio. One way to accomplish this is to provide investigators with a common set of tools and resources that allow their work to span the diverse areas of the minority health and health disparities. Social determinants of health—the conditions in which people are born, grow, live, work and age—are known to drive health disparities. Please see announcement for full details and direct all inquiries to: Nishadi Rajapakse, PhD, MHS; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-496-4338; Email: chandima.rajapakse@nih.gov

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
(PAR-20-313)
National Cancer Institute

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI.
Application Receipt Date(s): July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
(PAR-20-314)
National Cancer Institute

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity.
Application Receipt Date(s): July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023

NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)
(PAR-21-032)
National Institute of Neurological Disorders and Stroke

The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position.  This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact.
Application Receipt Date(s): June 9, 2021, October 14, 2021, February 9, 2022, June 8, 2022, October 11, 2022, February 9, 2023, June 8, 2023, and October 10, 2023.

NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)
(PAR-21-046)
National Library of Medicine

This Funding Opportunity Announcement (FOA) solicits grant applications for the preparation of book-length manuscripts and other works of academic and/or public health policy value to U.S. health professionals, public health officials, biomedical researchers and historians of the health sciences.

Letter of Intent Due Date(s): January 24, 2022 and January 24, 2023

Application Receipt Date(s): February 24, 2022 and February 24, 2023.

Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource Core (U24) (Clinical Trial Optional)
(RFA-AA-20-011)
National Institute on Alcohol Abuse and Alcoholism

This Funding Opportunity Announcement (FOA) solicits cooperative agreements to participate in two consortia under the Integrative Neuroscience Initiative on Alcoholism (INIA). This FOA solicits submission of administrative resource cores (U24) applications. Please see companion FOAs for submission of resource-related and support cores (U24) applications, RFA-AA-20-012, and for submission of collaborative research projects (U01) applications, RFA-AA-20-013 .

Letter of Intent Due Date(s): April 26, 2021

Application Receipt Date(s): May 26, 2021

Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24) (Clinical Trial Optional)
(RFA-AA-20-012)
National Institute on Alcohol Abuse and Alcoholism

This Funding Opportunity Announcement (FOA) solicits research cooperative agreements to participate in two consortia under the Integrative Neuroscience Initiative on Alcoholism (INIA). This FOA solicits submission of Research Resource core applications (U24) to support the consortium. Please see companion RFA-AA-20-011 for submission of an Administrative Resource core (U24) application, and companion RFA-AA-20-013 for submission of Research Project applications (U01).

Letter of Intent Due Date(s): April 26, 2021
Application Receipt Date(s): May 26, 2021

Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia (U01 Clinical Trial Optional)
(RFA-AA-20-013)
National Institute on Alcohol Abuse and Alcoholism

This Funding Opportunity Announcement (FOA) solicits cooperative agreements to participate in two consortia under the Integrative Neuroscience Initiative on Alcoholism (INIA). This FOA solicits research projects (U01) applications. Please see the companion FOA, RFA-AA-20-011 for submission of administrative resource cores applications, and companion FOA, RFA-AA-20-012 for submission of resource-related and support cores applications.

Letter of Intent Due Date(s): April 26, 2021
Application Receipt Date(s): May 26, 2021

From Genomic Association to Causation: A Convergent Neuroscience Approach to Linking Levels of Analysis for Understanding Neuropsychiatric Disorders (U19 Clinical Trial Optional)
(RFA-MH-21-165)
National Institute of Mental Health

This Funding Opportunity Announcement (FOA) supports research to understand causal linkages across different scales (e.g., molecular, cellular, circuit, behavioral, clinical) relevant to neuropsychiatric disorders. The Convergent Neuroscience (CN) program goal is to establish theoretical models to show how specific constituent processes at one level of analysis contribute to quantifiable properties at other levels, either directly or as emergent phenomenon.

Letter of Intent Due Date(s): 30 days before application due date
Application Receipt Date(s): March 17, 2021

National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional)
(PAR-20-306)
National Institute of Dental and Craniofacial Research

This Funding Opportunity Announcement (FOA) intends to support innovative, interdisciplinary research in several areas, including basic, NeuroHIV, behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementation science. The intent of D-ARC support is that the proposed core activities will allow the D-ARC to compete successfully for a full NIMH AIDS Research Center (ARC) after the D-ARC award period.

Letter of Intent Due Date(s):  30 days prior to the application due date
Application Receipt Date(s): August 25, 2021, August 25, 2022, and August 25, 2023.

Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
(PAR-20-307)
National Institute of Mental Health

This Funding Opportunity Announcement (FOA) intends to support innovative, interdisciplinary research in several areas, including basic, NeuroHIV, behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementation science. The intent of D-ARC support is that the proposed core activities will allow the D-ARC to compete successfully for a full NIMH AIDS Research Center (ARC) after the D-ARC award period.

Letter of Intent Due Date(s):  30 days prior to the application due date
Application Receipt Date(s): August 25, 2021, August 25, 2022, and August 25, 2023.

AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
(PAR-20-308)
National Institute of Mental Health

The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support HIV/AIDS Research Centers (ARC). The ARC is intended to provide infrastructure support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission. This Funding Opportunity Announcement (FOA) intends to support innovative, interdisciplinary research in several areas, including basic, NeuroHIV, behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementation science. 

Letter of Intent Due Date(s):  30 days prior to the application due date
Application Receipt Date(s): August 25, 2021, August 25, 2022, and August 25, 2023

Health Services Research on Minority Health and Health Disparities (R01- Clinical Trial Optional)
(PAR-20-310)
National Institute on Minority Health and Health Disparities, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, Office of Behavioral and Social Sciences Research, Office of Disease Prevention, Office of Research on Women's Health
he purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.

Application Receipt Date(s): November 17, 2021; March 17, 2022; November 17 2022; February 17, 2023.

Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed)
(PAR-21-027)
National Heart, Lung, and Blood InstituteThis Funding Opportunity Announcement (FOA) seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.

Letter of Intent Due Date(s):  30 days prior to application due date
Application Receipt Date(s): May 7, 2021, January 7, 2022, May 7, 2022, January 7, 2023

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
(PAR-21-044)
National Institute on Drug Abuse

The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, serum, and genomic DNA) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study.
Application Receipt Date(s): April 30, 2021, October 29, 2021, April 29, 2022, October 31, 2022, April 28, 2023, October 31, 2023.

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)
(RFA-CA-20-046)  National Cancer Institute

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to advance our understanding of: the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and the risk factors for infection.

Letter of Intent Due Date(s):  30 days prior to the application due date
Application Receipt Date(s): December 14, 2021

Otolaryngology Residency Mentored Research Pathway (R25 Clinical Trial Not Allowed)
(RFA-DC-20-002) National Institute on Deafness and Other Communication Disorders

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this NIDCD R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.
Application Receipt Date(s): June 10, 2021; February 10, 2022; October 11, 2022; June 13, 2023 apply.

BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)
(RFA-MH-20-620)
National Institute of Mental Health, National Center for Complementary and Integrative Health, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Neurological Disorders and Stroke, Office of Behavioral and Social Sciences Research

The purpose of the The Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative.

Letter of Intent Due Date(s): July 10, 2021, March 11, 2022, November 9, 2022
Application Receipt Date(s): August 10, 2021, April 11, 2022, December 9, 2022

NIAID Research Education Program (R25 Clinical Trial Not Allowed)
(PAR-20-289) National Institute of Allergy and Infectious Diseases

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. Application Receipt Date(s): December 7, 2021; and December 7, 2022.

Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03 Clinical Trial Not Allowed)
(PAR-20-290) National Institute of Allergy and Infectious Diseases
Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 16, 2020 and subsequent receipt dates through September 8, 2023.

Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed)
(PAR-20-291) National Institute of Allergy and Infectious Diseases
Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 16, 2020 and subsequent receipt dates through September 8, 2023.

Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)
(PAR-20-304) National Library of Medicine
NLM wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes. Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 5, 2021 and subsequent receipt dates through May 8, 2023.

Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites (U01 Clinical Trial Not Allowed)
(RFA-CA-20-043) National Cancer Institute
the National Cancer Institute (NCI) invites multiple-PD/PI applications for collaborative research projects each with two to three independent modeling groups that will comprise a new “incubator” program within the Cancer Intervention and Surveillance Modeling Network (CISNET). The overarching goal of this FOA is to expand comparative simulation modeling approaches developed by CISNET to new cancer organ sites beyond the sites which have been previously funded (breast, colorectal, prostate, lung, esophageal, and cervical) under CISNET. Application Receipt Date(s): January 20, 2021 No late applications will be accepted for this Funding Opportunity Announcement.

BRAIN Initiative: Pilot resources for brain cell type-specific access and manipulation across vertebrate species (U01 Clinical Trial Not Allowed)
(RFA-MH-20-556)

This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support the development of technologies, production efforts, and dissemination resources for a cell type-specific armamentarium to study brain function across species. The goal is to promote evaluation of molecular or genetic technologies and creation of pilot production and distribution resources for cell type-specific access and manipulation reagents for several vertebrate species, including in human ex vivo tissues or cells. Application Receipt Date(s): October 19, 2021.

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
(RFA-NS-21-010)

The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) https://heal.nih.gov/research/clinical-research/eppic-net or other Phase II clinical studies. Application Receipt Date(s): November 18, 2020, March 24, 2021, July 14, 2021, October 15, 2021, February 15, 2022, June 15, 2022.

Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03 Clinical Trial Not Allowed), Synopsis 1 - The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant (R03) support at some point during the final two years of their K award. NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.  Application due: June 16, 2021.  https://grants.nih.gov/grants/guide/pa-files/PAR-20-290.html

Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed), Synopsis 1 - The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and Developmental Research Grant (R21) support at some point during the final two years of their K award. NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R21 is, therefore, intended to support research projects that may provide preliminary data to support a subsequent R01, or equivalent, application.  Application due: June 16, 2021.  https://grants.nih.gov/grants/guide/pa-files/PAR-20-291.html

Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design
(NOT-AI-20-071) National Institute of Allergy and Infectious Diseases

The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection fromMycobacterium tuberculosis(Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals. Application Receipt Date(s): First available due date: October 5, 2020 and subsequent receipt dates through January, 8 2023. 

Notice of Special Interest (NOSI): Training Modules for Creating Safe, Inclusive, and Supportive Research Environments
(NOT-GM-20-047) National Institute of General Medical Sciences

The purpose of this Notice is to inform applicants of the topic areas for the June 18, 2021 due date of the NIGMS funding opportunity announcement (FOA) PAR-20-296 “Modules for Enhancing Biomedical Research Workforce Training (R25 - Clinical Trial Not Allowed)”. Application Receipt Date: June 18, 2021. 

Notice of Special Interest: Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities (R43/R44)
(NOT-HD-20-025) Eunice Kennedy Shriver National Institute of Child Health and Human Development

This notice invites small business applications specifically aimed at developing or building upon existing technological tools to improve assessments, interventions, and outcomes for children and individuals with intellectual, developmental and physical disabilities. Application Receipt Date(s): First available due date: January 5, 2021 and subsequent receipt dates through January, 8 2022. 

Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases
(NOT-HL-20-737) National Heart, Lung, and Blood Institute

This Notice of Special Interest (NOSI) encourages research grant applications focused on palliative care in patients with HLBS diseases across the lifespan. Collaboration between HLBS and palliative care researchers is encouraged. Palliative care research studies, including ancillary studies to ongoing clinical research studies, are encouraged. The NHLBI is interested in studies that focus on how to better integrate and implement palliative care into the management of patients with HLBS diseases. Application Receipt Date(s): First available due date: October 5, 2020 and subsequent receipt dates through July, 6 2023. 

Notice of Special Interest (NOSI): Research in the Emergency Setting
(NOT-NS-20-005)

This notice invites basic, translational and clinical research and career development programs that effect all areas of emergency medical care, including injury and trauma. Wherever appropriate, investigators are encouraged to utilize existing research networks, such as the NCATS supported CTSAs, NHLBI-NINDS supported SIREN emergency care research network, the NCI CONCERN oncology emergency research network, or the HRSA supported PECARN pedicatric critical care network. Application Receipt Date(s): First available due date: October 5, 2020 and subsequent receipt dates through September 8, 2022. 

Notice of Special Interest: Administrative Supplement for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp)
(NOT-NS-20-038) National Institute of Neurological Disorders and Stroke

The National Institute of Neurological Disorders and Stroke (NINDS) announces the availability of Administrative Supplements for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25 awards made in response to PAR-13-384, PAR-18-346) and subsequent reissuances. This announcement is for supplements to existing projects. To be eligible, the parent award must be active, and the research proposed in the supplement must be accomplished within the competitive segment. Application Receipt Date(s): First available due date: October 15, 2020 and subsequent receipt dates through October 30, 2022. 

Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 Clinical Trial Optional)
(PAR-20-293) National Institute of Mental Health

Funding Opportunity Announcement (FOA) invites applications for centers to support transdisciplinary teams of clinical and mental health services researchers, behavioral scientists, social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) to engage in high-impact studies that will significantly advance clinical practice and generate knowledge that will fuel transformation of mental health care in the United States. Application Receipt Date(s): May 17, 2021, May 17, 2022, May 17, 2023.

Modules for Enhancing Biomedical Research Workforce Training (R25 Clinical Trial Not Allowed)
(PAR-20-296) National Institute of General Medical Sciences

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. Specifically, this FOA will support the development of training modules designed to be freely available, at no cost to the broader community to enhance training of the biomedical research workforce. Responsive topics will be indicated through Notices of Special Interest (NOSIs) released annually by NIGMS.
Application Receipt Date(s): June 18, 2021; June 20, 2022; June 19, 2023.

Development of the Fetal Immune System (R01 Clinical Trial Not Allowed)
(PAR-20-298) Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases

The purpose of this Funding Opportunity Announcement (FOA) is to understand the contribution of specific elements of maternal molecular and cellular factors that can control and effect the development of the fetal immune system. Application Receipt Date(s): April 7, 2021, December 7, 2021, April 7, 2022, December 7, 2022, April 7, 2023, December 7, 2023.

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
(PAR-20-299) Eunice Kennedy Shriver National Institute of Child Health and Human Development
Office of Research on Women's Health

The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. Application Receipt Date(s): April 9, 2021, August 10, 2021, December 10, 2021, April 11, 2022, August 10, 2022, December 9, 2022.

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
(PAR-20-300) Eunice Kennedy Shriver National Institute of Child Health and Human Development
Office of Research on Women's Health

The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children.
Application Receipt Date(s): April 9, 2021, August 10, 2021, December 10, 2021, April 11, 2022, August 10, 2022, December 9, 2022.

Notice of Special Interest: Advancing the Science of Geriatric Palliative Care
(NOT-AG-20-041)

This Notice of Special Interest (NOSI) encourages research grant applications focused on palliative care in geriatric populations. This NOSI covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, long-term care facilities, hospices, and other healthcare or community settings. This NOSI encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources.  Application receipt date: this notice applies to standard due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2023. 

Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional)
(PAR-20-302) National Cancer Institute; Office of Disease Prevention

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Application Receipt Date(s): November 12, 2020; thereafter, Standard dates apply through September 8, 2023.

Tobacco Control Policies to Promote Health Equity (R21 Clinical Trial Optional)
(PAR-20-303) National Cancer Institute; Office of Disease Prevention

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations.
Application Receipt Date(s): November 12, 2020; thereafter, Standard dates apply through September 8, 2023.

HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
(PAR-21-024) National Institute of Allergy and Infectious Diseases

The purpose of this Funding Opportunity Announcement (FOA) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included.  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed here: March 15, 2021; March 15, 2022; March 15, 2023.

Toward ElucidAting MechanismS Contributing to HIV Reservoirs in NIDDK-relevant Tissues (Cure TEAMS) (R01 Clinical Trial Optional)
(RFA-DK-20-023) National Institute of Diabetes and Digestive and Kidney Diseases
The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and physiology, pathophysiology, pathobiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will provide comprehensive mechanistic analyses of the processes leading to the establishment and persistence of latent HIV reservoirs in anatomical sites relevant to the mission of the NIDDK, with the purpose of advancing progress toward developing a cure. Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed here: November 17, 2021.

Notice of Special Interest: Administrative Supplements for Connecting Pre-mortem Clinical Information with Post-Mortem Brain Analysis
(NOT-NS-21-001) National Institute of Neurological Disorders and Stroke

This NOSI encourages researchers with extensive pre- and post-mortem data on patients with LBD to apply for supplemental funds to be used for the purpose of adding this data to the existing NINDS PDBP repository.

First Available Due Date:  October 26, 2020 and subsequent receipt dates through June 29, 2021.

Mentored Career Development Program (K01) for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)
(PAR-20-258) National Institute of Allergy and Infectious Diseases; National Center for Complementary and Integrative Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and “protected time” (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application.  The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic.

Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 12, 2020 and subsequent receipt dates through January 8, 2023.

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
(PAR-20-292) National Cancer Institute

This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities.
Application Receipt Date(s): June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022

Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)
(PAR-20-295) National Cancer Institute

The purpose of this Funding Opportunity Announcement (FOA) is to bring a highly sensitive imaging technology capable of detecting very small (1-3 mm3) tumors in vivo to clinical utility. Through this FOA, the National Cancer Institute (NCI) solicits innovative concepts that propose a path to clinical validation for in vivo ‘intelligent’ or activated optical fluorescence agents or probes with previously demonstrated capabilities for the detection of small tumors.
Application Receipt Date(s): October 13, 2021

NIOSH Centers of Excellence for Total Worker Health (U19)
(PAR-20-297) National Institute for Occupational Safety and Health

NIOSH/CDC invites applications for the NIOSH Centers of Excellence for Total Worker Health (TWH). The purpose of this FOA is to solicit meritorious applications for Centers of Excellence for TWH to develop and conduct a broad range of multidisciplinary research, intervention, outreach and education, and evaluation activities that advance the overall safety, health, and well-being of the diverse population of workers in our nation.
Application Receipt Date(s): October 29, 2021; October 28, 2022; October 30, 2023 

Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
(RFA-DK-20-022) National Institute of Diabetes and Digestive and Kidney Diseases

The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Application Receipt Date(s): November 17, 2021

Notice of Special Interest: Alcohol and Aging
(NOT-AA-20-019) National Institute on Alcohol Abuse and Alcoholism

The purpose of this Notice of Special Interest (NOSI) is to promote research to improve our understanding of the effects of alcohol consumption on aging across different levels of biological organization including the molecular, cellular, tissue, organ, organism, and societal levels. The following broad research areas will be encouraged: 1) Basic and clinical research defining the effects of alcohol consumption on lifespan, health span, and age-related diseases depending on level of alcohol consumption, drinking pattern, and duration of drinking; 2) Research to inform evidence-based guidance for identifying risk for alcohol use disorder (AUD) among older adults as well as prevention, diagnosis, and treatment of AUD in this population; and 3) Research to extend the health span of older adults who drink and decrease the health care burden of age-related diseases associated with alcohol use.

First Available Due Date:  October 05, 2020 and subsequent receipt dates through September 8, 2023.

Notice of Special Interest: Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases
(NOT-DK-20-040) National Institute of Diabetes and Digestive and Kidney Diseases

The purpose of the NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD) Administrative Supplement Program is to enable additional clinical perspectives to be brought to on-going research projects within the Division's mission and to enhance the research expertise of selected physicians. The program will provide supplementary funds to support advanced research opportunities for exceptional emerging physician-scientists (hereafter, "candidates") holding the MD or equivalent or MD/PhD degrees, and who are early in their research careers. First Available Due Date:  Wednesday, February 3, 2021 for awards in June to August 2021, with subsequent due dates of Thursday, February 3, 2022 for awards in June to August 2022, and Friday, February 3, 2023 for awards in June to August 2023.

Disseminating and Implementing Patient-Centered Outcomes Research (PCOR) Evidence into Practice through Interoperable Clinical Decision Support
(PA-20-074) Agency for Healthcare Research and Quality

This Funding Opportunity Announcement invites R18 grant applications that disseminate and implement patient-centered outcomes research evidence in clinical practice by scaling computer-based, interoperable clinical decision support. Application Receipt Date(s): Standard dates apply. The first standard due date for the FOA is January 25, 2021 and subsequent receipt dates through January 26, 2022.

Research to Improve Native American Health (R21 Clinical Trials Optional)
(PAR-20-214) National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is to support developmental/exploratory studies in preparation for health promotion, disease prevention, treatment, or treatment services research to improve health in Native American (NA) populations. Application Due Date(s): May 17, 2021; May 17, 2022; May 17, 2023

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)
(PAR-20-238) National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is to support research on interventions to improve health in Native American (NA) populations. Application Due Date(s): May 17, 2021, May 17, 2022, May 17, 2023

NLM Information Resource Grants to Reduce Health Disparities (G08 Clinical Trial Not Allowed).
(PAR-20-283) National Library of Medicine; Office of Research on Women's Health

This Funding Opportunity Announcement (FOA) solicits resource grant applications for projects that will bring useful, usable health information to health disparity populations and their health care providers. Access to useful, usable, understandable health information is an important factor when making health decisions. Proposed projects should exploit the capabilities of computer and information technology and health sciences libraries to bring health-related information to consumers and their health care providers. Letter of Intent Due Date(s): September 22, 2021, September 21, 2022. Application Due Date(s): October 22, 2021, October 21, 2022, respectively.

NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional)
(RFA-HD-21-023) Eunice Kennedy Shriver National Institute of Child Health and Human Development

This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications to support integrated, multi-project research programs that address HIV scientific areas relevant to the NICHD mission as a well-defined, central research focus or objective.  Application Due Date(s): Only accepting applications for the AIDS Application Due Date:  March 31, 2021

Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities (NOT-MD-20-025)

The purpose of this Notice of Special Interest is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities.

First Available Due Date: October 05, 2020 and subsequent receipt dates through May 8, 2023. 

Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations
(NOT-MD-20-026) National Institute on Minority Health and Health Disparities

The purpose of this Notice of Special Interest is to support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations.

First Available Due Date: October 5, 2020 and subsequent receipt dates through May 8, 2021.

Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
(PAR-20-263) National Institute of Mental Health

This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays.
First Available Due Date: October 5, 2020 and subsequent receipt dates through September 08, 2023.

Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
(PAR-20-264) National Institute of Mental Health

This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays.
First Available Due Date: September 16, 2020 and subsequent receipt dates through September 08, 2023.

Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)
(PAR-20-284) National Cancer Institute

This Funding Opportunity Announcement (FOA) entitled "Innovative Research in Cancer Nanotechnology (IRCN)" encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems.
Application Due Date(s): May 6, 2021, November 4, 2021, May 5, 2021, November 3, 3022, May 4, 2023

NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed)
(PAR-20-259) National Institute of Allergy and Infectious Diseases

The NIAID New Innovator Awards supports Early Stage Investigators of exceptional creativity who propose novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use novel of methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.  

Application Receipt Date(s): October 14, 2021; October 14, 2022

Notice of Special Interest: Sex and Gender Differences in Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD)
(NOT-AG-20-038) National Institute on Aging

This Notice of Special Interest (NOSI) is intended to promote multidisciplinary research to clarify sex and gender differences in the risk, development, progression, diagnosis, and clinical presentation of Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD). Studies that examine sex and gender differences in outcomes (e.g., clinical, functional, well-being) among people living with AD/ADRD are also relevant. First Available Due Date:  November 12, 2020 and subsequent receipt dates through November 13, 2021. 

Notice of Special Interest: Basic and Translational Research on Affective, Motivational, and Social Function in Normative Aging and/or Alzheimers Disease and Related Dementias (AD/ADRD)
(NOT-AG-20-040) National Institute on Aging

This Notice of Special Interest (NOSI) is intended to underscore NIA’s continued commitment to psychological and neuroscientific research on affective, motivational, and social functions in midlife and aging. NIA supports research to further clarify the changes in and trajectories of these processes in adults who are aging normally and/or in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). First Available Due Date:  October 05, 2020 and subsequent receipt dates through January 8, 2022.

Notice of Special Interest (NOSI): Discovery of Analgesic Natural Products through the NINDS IGNITE Program
(NOT-AT-20-016) National Center for Complementary and Integrative Health

The purpose of this Notice of Special Interest (NOSI) is to announce NCCIH participation in the NINDS IGNITE program. For this NOSI, NCCIH is interested in supporting research geared toward development of robust, validated analgesic assays suitable for medium- to high-throughput screening of natural product libraries. First Available Due Date:  October 20, 2020 and subsequent receipt dates through May 8, 2021.

Notice of Special Interest (NOSI): Platform Trials of Thrombectomy in Acute Stroke Treatment
(NOT-NS-20-095) National Institute of Neurological Disorders and Stroke

The NINDS is issuing this Notice of Special Interest in applications to establish a master protocol to conduct platform trials for treatments of ischemic stroke due to large vessel occlusion. Master protocols should incorporate advanced clinical trial methodologies such as, but not limited to, Bayesian modeling, response adaptive randomization, shared controls, and the ability for treatment arms to enter, leave, or be combined. Master protocols must be designed to allow future addition of trial questions. First Available Due Date:  October 14, 2020 and subsequent receipt dates through July 14, 2021.

NIAID Clinical Trial Planning Grant (R34 Clinical Trials Not Allowed)
(PAR-20-270) National Institute of Allergy and Infectious Diseases

This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute.  Application Receipt Date(s):  May 12, 2021; September 14, 2021; January 12, 2022; May 13, 2022; September 14, 2022; January 13, 2023; May 12, 2023.

Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional)
(PAR-20-286) National Institute of Mental Health

This Funding Opportunity Announcement (FOA) invites applications for research centers to support integrated programs of high-impact, practice-based research with near-term potential to address NIMH suicide prevention priorities and help achieve the National Action Alliance for Suicide Prevention goals of reducing the rate of suicide in the US. Application Receipt Date(s): May 26, 2021 and January 26, 2022.

Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed)
(PAR-20-294) National Cancer Institute

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support the maintenance of existing CECs infrastructure and resource sharing with broader scientific communities. Application Receipt Date(s):  April 9, 2021; November 9, 2021; April 7, 2022; November 9, 2022

BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional)
(RFA-MH-20-600)

This Funding Opportunity Announcement (FOA) solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives teams will work with the research community to incorporate tools that allow users to analyze and visualize the data, but the creation of such tools is not part of this FOA. Application Receipt Date(s): July 14, 2021, July 14, 2022, and July 14, 2023 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement.

Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed)
(PA-20-252) Office of Dietary Supplements; National Cancer Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Center for Complementary and Integrative Health

The rigor and reproducibility of research on dietary supplements are enhanced by rigorous characterization of key experimental resources and biological samples. The dissemination of analytical methods that are validated to accurately and reliably characterize dietary supplements and quantify their constituents and/or metabolites is vital for both basic and clinical research. This FOA builds on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of analytical methods for dietary supplements and other natural products.

Application Receipt Date(s): April 15, 2021, October 15, 2021, January 17, 2022, and April 15, 2022

Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional)
(PAR-20-254)  National Human Genome Research Institute; National Cancer Institute; National Eye Institute; National Heart Lung and Blood Institute; National Institute on Aging; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  Applications may propose studies using either single or mixed methods.  Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Application Receipt Date(s): New Application Due Dates: June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023 Renewal, Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21) (Clinical Trial Optional)
(PAR-20-255) National Human Genome Research Institute; National Cancer Institute; National Eye Institute; National Institute on Aging; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke

This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Application Receipt Date(s): New Application Due Dates: June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023 Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023

Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03) Clinical Trial Optional)
(PAR-20-257) National Human Genome Research Institute; Fogarty International Center; National Cancer Institute; National Institute on Aging; National Institute of Environmental Health Sciences; National Institute of Mental Health

This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

Application Receipt Date(s): New Application Due Dates: June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023 Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023

Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)
(PAR-20-279)  National Institute on Drug Abuse & National Institute on Alcohol Abuse and Alcoholism

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.
Application Receipt Date(s): August 10, 2021; December 14, 2021; August 10, 2022; December 14, 2022; August 10, 2023

NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
(PAR-20-285) National Institute of Neurological Disorders and Stroke

This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet.
Application Receipt Date(s): New Applications: June 18, 2021; October 14, 2021; February 22, 2022; June 20, 2022; October 18, 2022; February 14, 2023, June 14, 2023 by 5:00 PM local time of applicant organization. Resubmission or Revision Applications: November 18, 2020; March 22, 2021; July 14, 2021; November 18, 2021, March 22, 2022; July 20, 2022; November 18, 2022; March 14, 2023, July 23, 2023

NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
(RFA-DK-20-024) National Institute of Diabetes and Digestive and Kidney Diseases

The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK's Division of Digestive Diseases and Nutrition.
Application Receipt Date(s): January 06, 2021 

Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01, Clinical Trial Optional)
(RFA-HG-20-048) National Human Genome Research Institute & National Cancer Institute

The purpose of this initiative is to support investigator-initiated research on genetic counseling processes and practices in genomic medicine. Research is needed to optimize the genetic counseling process in the context of limited resources. Application Receipt Date(s): July 8, 2021

Notice of Special Interest: Fundamental and Translational Research on Decision Making in Aging and/or Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD)
(NOT-AG-20-039) National Institute on Aging

This Notice of Special Interest (NOSI) underscores NIA’s continued commitment to research that seeks to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). Research is sought that characterizes the extent to which behavioral, psychological, and neural processes involved in decision making are differentially impacted in normal aging, MCI, and AD/ADRD. This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through January 8, 2022.  First available due date is October 5, 2020.

Notice of Special Interest (NOSI): Improving Methods to Assess Body Composition in Infants and Young Children
(NOT-DK-20-036) National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Biomedical Imaging and Bioengineering

The purpose of this Notice is to inform potential applicants to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in research to improve methods to assess body composition in infants and young children ages birth through 5 years. This notice applies to due dates on or after September 5, 2020 and subsequent receipt dates through September 5, 2022.  First available due date is September 5, 2020.

Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) (PAR-20-271)
National Cancer Institute; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health

Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 5, 2020 and subsequent receipt dates through January 08, 2023.

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) (PAR-20-276)
National Cancer Institute; National Human Genome Research Institute; National Institute of Dental and Craniofacial Research

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.).
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 5, 2020 and subsequent receipt dates through September 8, 2022.

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) (PAR-20-277)
National Cancer Institute; National Human Genome Research Institute; National Institute of Dental and Craniofacial Research

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.).
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 16, 2020 and subsequent receipt dates through September 8, 2022.

Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional) (PAR-20-281)
Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institute of Environmental Health Sciences; Office of Disease Prevention; Office of Research on Women's Health

The purpose of this funding opportunity (FOA) is to support research that explores the premise that fertility status can be a marker for overall health.
Application Receipt Date(s): June 19, 2021, February 19, 2022, October 19, 2022, June 19, 2023

Fertility Status as a Marker for Overall Health (R21 Clinical Trial Not Allowed) (PAR-20-282)
Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute;
National Institute of Environmental Health Sciences; Office of Disease Prevention; Office of Research on Women's Health

The purpose of this funding opportunity announcement (FOA) is to support exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as cancer, diabetes, and obesity can impair fertility; however, less is known about the extent to which fertility status can impact or act as a marker for overall health.
Application Receipt Date(s): October 19, 2020, June 19, 2021, February 19, 2022, October 19, 2022, June 19, 2023 

NIEHS Research Intensive Short Courses and Educational Opportunities (NIEHS RISE) (R25 Clinical Trial Not Allowed)
(RFA-ES-20-015) National Institute of Environmental Health Sciences

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
Application Receipt Date(s): November 29, 2021, November 28, 2022

Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional)
(PAR-20-254)

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  Applications may propose studies using either single or mixed methods.  Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Application Receipt Date(s): New Application Due Dates: June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023 Renewal, Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21) (Clinical Trial Optional)
(PAR-20-255)

This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21)  applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Application Receipt Date(s): New Application Due Dates: June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023

Resubmission and Revision Due Dates: March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023

Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)
(PAR-20-279) National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs).

Application Receipt Date(s): August 10, 2021; December 14, 2021; August 10, 2022; December 14, 2022; August 10, 2023

Notice of Special Interest: Epidemiology and Prevention in Alcohol Research
(NOT-AA-20-017)  National Institute on Alcohol Abuse and Alcoholism

Advancing knowledge about the epidemiology of alcohol use is fundamental to improving the public health. One prominent objective is to better understand the developmental trajectories of alcohol use, risky drinking, and alcohol use disorders. However, much is unknown about the train of events between early initiation, frequent heavy drinking, and the development of an alcohol use disorder. Much is also unknown about how the various risk factors in this train of events interact with each other. The ways in which epigenetic changes in gene expression are produced by interactions with environmental influences are only beginning to be understood. Similarly, little is known about the correlates of "maturing out" of heavy drinking, which happens in most individuals, but not all.

The first available due date is on or after October 5, 2020 and subsequent receipt dates through September 8, 2023.

Notice of Special Interest: Notice of Availability of Funds for Administrative Supplements for Pediatric Radiation/Nuclear Animal Models, MCM, Biodosimetry Development
(NOT-AI-20-061) National Institute of Allergy and Infectious Diseases

The NIAID/Radiation and Nuclear Countermeasures Program (RNCP) has been tasked with developing safe and effective medical countermeasures (MCMs) and biodosimetry tools for civilians, which can be used at least 24 hours post-exposure during a radiological or nuclear public health emergency. The goal of this initiative is to promote pediatric-specific research to enable the advancement of pediatric MCMs and biodosimetry tools. This is currently an unmet need that impacts the safety and public health of the pediatric population. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent. PA-18-591- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).

Application Due Date(s) – November 1, 2021; November 1, 2022.

Notice of Special Interest (NOSI): Obesity Policy Evaluation Research (R01 Clinical Trial Not Allowed)
(NOT-DK-20-035)
The purpose of this Notice is to inform potential applicants of NIH’s interest in research evaluating large-scale policies or programs implemented at the local, state or national level that are expected to influence obesity-related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes with a goal of preventing or reducing rates of obesity. The focus of this FOA is on research in humans, not animals. This FOA encourages innovative scientific partnerships between researchers and public or private partners (e.g., community-based organizations, local governments, school districts, employers, etc.).

The first available due date is on or after October 5, 2020 and subsequent receipt dates through September 8, 2023.

Notice of Special Interest: Fundamental and Translational Research on Decision Making in Aging and/or Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD)
(NOT-AG-20-039) National Institute on Aging

This Notice of Special Interest (NOSI) underscores NIA’s continued commitment to research that seeks to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). Research is sought that characterizes the extent to which behavioral, psychological, and neural processes involved in decision making are differentially impacted in normal aging, MCI, and AD/ADRD. Investigations that target the influence of social factors on decision making or other factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse are of particular interest.

The first available due date is on or after October 5, 2020 and subsequent receipt dates through January 08, 2022.

Notice of Special Interest (NOSI): Stimulating Intervention Research to Reduce Cardiopulmonary Impacts of Particulate Matter in Air Pollution among High-Risk Populations
(NOT-HL-20-788)
National Heart, Lung, and Blood Institute & National Institute of Environmental Health Sciences

The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the NHLBI and the NIEHS have special interest in applications aiming to investigate the impact of personal interventions to reduce exposure to particulate matter (PM) in air pollution on cardiovascular and pulmonary (cardiopulmonary) outcomes. This notice specifically encourages intervention studies or clinical trials that examine the efficacy of personal air pollution interventions to reduce the adverse cardiopulmonary effects of Particulate Matter (PM) <2.5 µm in diameter (PM2.5) in high risk or vulnerable participants.

The first available due date is on or after October 5, 2020 and subsequent receipt dates through

September 7, 2025.

NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
(PAR-20-267) National Institute on Drug Abuse

NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to substance use/misuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged.
Application Receipt Date(s): September 27, 2021, September 26, 2022

BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed)
(RFA-DA-21-006)

The purpose of this FOA is to develop tools and technologies to conduct scientifically rigorous, ethical, efficient, and cost-effective research, as well as develop necessary infrastructure, that supports germline and somatic transgenic and gene editing studies in the common marmoset (Callithrix jacchus). These studies should answer crucial scientific questions that require genetic perturbation in a non-human primate model organism, as well as support the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) goals of understanding the brain in health and disease.

Application Receipt Date(s): October 14, 2021 

NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional)
(RFA-NS-21-001) National Institute of Neurological Disorders and Stroke

This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinson’s Disease Research program. The overarching goal of this program is to support specialized research Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson’s disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research.
Application Receipt Date(s): September 28, 2021, September 28, 2022

Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
(PAR-20-271)
National Cancer Institute, National Institute on Deafness and Other Communication Disorders & National Institute of Mental Health

Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.
Application Receipt Date(s): Standard dates apply. This funding mechanism expires on January 08, 2023. The first standard due date for this FOA is October 5, 2020

NIEHS Research Intensive Short Courses and Educational Opportunities (NIEHS RISE) (R25 Clinical Trial Not Allowed)
(RFA-ES-20-015)
National Institute of Environmental Health Sciences

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
Application Receipt Date(s): November 29, 2021, November 28, 2022

Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)
(PAR-20-253)

This Funding Opportunity Announcement (FOA) encourages applications for NIH Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental (R21) projects. The mission of the NIH CounterACT program is to foster and support research that will advance development of new and improved therapeutics to mitigate the health effects of chemical threats.

Application Receipt Date(s): May 26, 2021; May 31, 2022; May 30, 2023

Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders
(NOT-DA-20-058) National Institute on Drug Abuse

The purpose of this NOSI is to stimulate research to evaluate the safety and efficacy of telemedicine or remotely provided treatments for SUD, and to develop tools for remote collection of data in clinical trials of treatments for SUD.

Standard deadlines apply; first available due date for this opportunity is October 5, 2020.

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
(PAR-20-249) National Institute on Drug Abuse

This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research  and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research.
Application due date(s): August 2, 2021, November 15, 2021, March 1, 2022, August 2, 2022, November 15, 2022, March 1, 2023, August 2, 2023, November 15, 2023

NICHD Research Education Programs (R25 Clinical Trial Not Allowed)
(PAR-20-250) Eunice Kennedy Shriver National Institute of Child Health and Human Development and
National Center for Advancing Translational Sciences

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
Application Receipt Date(s): Standard dates apply. The first standard application due date for this FOA is September 25, 2020.

BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trial Not Allowed)
(RFA-EB-20-001)

This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development of entirely new noninvasive imaging methods or unusually bold approaches for existing noninvasive imaging methods that will lead to transformative advances in our understanding of the function and connectivity of the human brain. The FOA solicits small-scale projects to prove exceptionally innovative, original and/or unconventional concepts.

Application Receipt Date(s): September 3, 2021 No late applications will be accepted for this Funding Opportunity Announcement.

NIH Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)
(PAR-20-240) National Institute of Neurological Disorders and Stroke; National Institute of Mental Health

The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research 

Application Receipt Date(s): September 27, 2021, and September 26, 2022 Application Receipt Date(s): January 25, 2021, September 27, 2021, and September 26, 2022 

Notice of Specialist Interest (NOSI): Advancing Polycystic Kidney Disease (PKD) Research through Catalytic Tool and Technology Development
(NOT-DK-20-034) National Institute of Diabetes and Digestive and Kidney Diseases

This is an opportunity for investigators to apply for funding for developing novel tools and technologies that enable new lines of scientific inquiry and/or treatment, prevention, or diagnosis of Polycystic Kidney Disease (PKD).

This notice applies to due dates on or after October 16, 2020 and subsequent receipt dates through January 8, 2023.

Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)
(PAR-20-232) National Institute of Dental and Craniofacial Research

This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices.
Application Receipt Date(s): Standard dates apply The first standard due date for this FOA is October 16, 2020.

Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)
(NOT-HL-20-796) National Heart, Lung, and Blood Institute

The purpose of this Notice of Special Interest is to inform potential applicants to the National Heart, Lung and Blood Institute (NHLBI) of an area of special interest in exploring bold, new bioengineering approaches or concepts, including computationally-efficient methods, that are important to a substantive heart, lung, blood or sleep area, and in supporting the early phases of these innovative bioengineering projects which are, in turn, expected to transition into research to translate them into practice, technologies, or commercial products.

First Available Due Date: July 17, 2020

Expiration Date: July 16, 2021

Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01)
(PAR-20-230) National Human Genome Research Institute
Application Receipt Date(s): Applications are accepted by continuous receipt.

Expiration Date July 9, 2023

The Center for Inherited Disease Research (CIDR) high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes or genetic modifications that contribute to human health and disease or to enhance existing collections of well-phenotyped specimens by the addition of genotype or next-generation sequence data.

Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 No Independent Clinical Trials)

(PAR-20-211)

The program will support career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes. Applicants may propose research that involves non-human animals, secondary data analyses, or other career development projects that do not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial.

Application due dates: March 17, 2021, March 17, 2022, March 17, 2023

Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 Basic Experimental Studies with Humans Required)

(PAR-20-226)

This program will support career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes. Eligible candidates are independent investigators at mid-career faculty rank or level.

Application due dates: March 17, 2021, March 17, 2022, March 17, 2023

Advancing Genomic Medicine Research (Clinical Trial Optional) (R01)

(RFA-HG-20-036) NHGRI

This (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.

Application due dates: November 2, 2021; August 1, 2022; March 13, 2023

Advancing Genomic Medicine Research (Clinical Trial Optional) (R21)

(RFA-HG-20-037) NHGRI

This (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.

Application due dates: November 2, 2021; August 1, 2022; March 13, 2023.

Notice of Special Interest (NOSI): Research on Co-morbid Substance Use, Substance Use Disorders, and Other Psychiatric Disorders

(NOT-DA-20-004) National Institute on Drug Abuse & Office of Research on Women's Health

The purpose of this Notice is to encourage the submission of research project grant applications that address co-morbid substance use and/or substance use disorders, and other psychiatric disorders. Research in response to this NOSI may include etiologic investigations to inform prevention intervention, intervention development and testing, and research to address service delivery strategies to address co-morbid conditions. The intent is to encourage a broad portfolio of research, that enhances understanding of risk, etiology, prevention, treatment and service delivery related to co-occurring conditions.

First available due date: October 5, 2020

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
(PA-20-222)

Application Due dates vary by awarding IC.  Please see Table of IC-Specific Information, Requirements and Staff Contacts for more details.

Funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project.  Administrative supplements must support work within the scope of the original project.

Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1 - Clinical Trial Not Allowed)
(PAR-20-220)

Application Due Dates: September 28, 2021, September 28, 2022

The purpose of this funding opportunity is to invite new Institutional Network Awards (U2C/TL1) to cultivate a highly integrated cohort of trainees and early career investigators and to develop career development resources to accelerate kidney, urologic, and hematologic research.

Notice of Special Interest: Promoting Fundamental and Applied Research in Inflammation Resolution
(NOT-ES-20-018)

The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Environmental Health Sciences, the National Heart, Lung, and Blood Institute, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases have special interest in applications to investigate the mechanisms controlling the resolution of inflammation in chronic disease states.

Application Due Dates: Vary depending on IC and FOA being applied under; please see individual IC dates for additional information.  First available due date for these opportunities is October 5, 2020.

Related FOAs:

  • NIEHS will accept applications submitted under PA-20-195, PA-20-185, PA-20-184, and PA-20-196.
  • NHLBI will accept applications submitted under PA-20-183 and PA-20-185. Support of mechanistic clinical trials will be allowed. For mechanistic clinical trial submissions, refer to NOT-HL-18-611: NHLBI Policy Regarding Submission of Clinical Trial Applications.
  • NIAMS will accept applications submitted under PA-20-195 and PA-20-185.

PAR-19-242Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)

National Cancer Institute

The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists (M.D.s, D.O.s, Pharm.D.s, nurses with Ph.D.s, or equivalent) trained in clinical and translational cancer research, and to promote their career development as cancer researchers.

Application Receipt Date(s): June 17, 2021 *See (NOT-CA-20-069) for Notice of Change: Late Application Policy for June 17, 2020, Application Due Date of PAR-19-242, Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) Due to Public Health Emergency for US Coronavirus Disease 2019

Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions (NOT-OD-20-106)
Office of Behavioral and Social Sciences Research, National Center for Complementary and Integrative Health, National Cancer Institute, National Institute on Aging, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute on Drug Abuse, National Institute of Dental and Craniofacial Research, National Institute of Mental Health, National Institute of Nursing Research

The Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Notice to highlight interest in the systematic development of novel health-related behavioral interventions that leverage new, emerging or understudied areas in basic behavioral and social sciences research (bBSSR). To achieve more potent and sustained strategies to promote health-related behavior change, there is a need for intentional and methodical translation of foundational behavioral and social science discoveries into new or improved interventions. This includes research that focuses on use-inspired bBSSR, understanding of mechanisms of action underlying initial and sustained behavior change, and systematic development and testing of health-related behavioral interventions and their components.

Application due dates vary depending on Institute and FOA; please see FOA for specific due dates for submission of proposals.

Related Announcements to Apply under:

  • PAR-19-213 - Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)
  • PAR-19-212 - Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)
  • PA-18-849 - Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)
  • PA-18-850 - Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)
  • PA-18-722 - Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)
  • PA-18-723 - Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R21 Clinical Trial Optional)
  • PAR-18-581 - Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 - Clinical Trial Optional)
  • PAR-18-877 - Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)
  • PAR-20-070 - Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)
  • PAR-19-070 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
  • PA-20-184- NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  • PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)
  • PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
  • PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
  • PAR-18-069 - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
  • PAR-19-309 - Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)
  • PAR-18-559 - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
  • PAR-18-307 - Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)
  • PAR-18-892 - Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)
  • PAR-18-893 - Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)
  • PAR-18-656 - NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
  • PA-18-932 - Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)
  • PAR-18-612 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 Clinical Trial Optional)
  • PAR-18-611 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 Clinical Trial Optional)
  • PA-18-729 - Research on the Health of Transgender and Gender Nonconforming Populations (R01 Clinical Trial Optional)
  • PA-18-728 - Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional)
  • PAR-19-274 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
  • PAR-19-275 - Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
  • PAR-17-491 - Implementing the Most Successful Interventions to Improve HIV/AIDS Outcomes in U.S. Communities (R01 Clinical Trial Optional)
  • PA-18-849 - Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)
  • PA-18-945 - Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)
  • PA-18-944 - Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)
  • PA-18-943 - Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)
  • PAR-19-045 - End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)
  • PAR-19-044 - End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21 Clinical Trial Optional)
  • PAR-19-057 - Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial Optional)
  • PAR-19-058 - Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional)
  • PAR-19-136 - End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)
  • PAR-19-153 - End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)
  • PAR-19-321- Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)
  • PAR-19-320 - Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)
  • PAR-18-595 - Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required)
  • PA-18-592 - Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed)
  • RFA-MH-18-704 - Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 - Clinical Trial Required)
  • RFA-MH-18-705- Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 - Clinical Trial Required)
  • RFA-MH-18-706 - Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 - Clinical Trial Required)
  • PA-20-141 - Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 - Clinical Trial Optional)
  • PA-18-322 - Fundamental Science Research on Mind and Body Approaches (R21 Clinical Trial Optional)
  • PA-18-323 - Fundamental Science Research on Mind and Body Approaches (R01 Clinical Trial Optional)

National Institutes of Health, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation.  The objective of the NIH Mentored Clinical Scientist Research Career Development Award (K08) is to provide salary and research support for a sustained period of "protected time" (3-5 years) to support didactic study and/or mentored research for individuals with clinical doctoral degrees.

Application Receipt Date(s): Standard dates apply. The first standard application due date for this FOA is June 12, 2020.

National Institutes of Health, National Center for Complementary and Integrative Health, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute on Minority Health and Health Disparities, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research
The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.

National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH)

The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty.

Standard due dates apply.  The first standard application due date for this FOA is June 12, 2020.

NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)
(PAR-20-210) National Institute of Allergy and Infectious Diseases

The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. The objective of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) is to help address the current shortage of physicians who conduct biomedical research by offering this career development opportunity.
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 12, 2020.

Metastasis Research Network (U54 Clinical Trial Not Allowed)
(RFA-CA-20-029) National Cancer Institute

The purpose of this Funding Opportunity Announcement (FOA) is to develop a comprehensive and cohesive understanding of cancer metastasis. Towards this goal, the National Cancer Institute (NCI) will support several U54 Specialized Centers that together will form the Metastasis Research Network (MetNet). Each MetNet Center should propose an overarching scientific theme that will be pursued through two or three scientific inter- and multi-disciplinary basic research projects.
Application Receipt Date(s): May 28, 2021

PAR-19-207 Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)

National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this IC Name R25 program is to support educational activities that complement and/or foster a better understanding of biomedical, behavioral and clinical research and its implications.

Application due dates: August 10, 2021, November 15, 2021, March 15, 2022, August 10, 2022.

RFA-MH-20-120 BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)

National Institute of Mental Health (NIMH), National Eye Institute (NEI), National Institute on Aging (NIA) National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS)

PAR-19-368 Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional). National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Cancer Institute ( NCI ).

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Standard application due dates apply; first available due date for this opportunity is June 5, 2020.

Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional) - The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed here (https://www.drugabuse.gov/funding/funding-priorities) or within the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031). Standard application due dates apply. The first standard due date for this FOA is June 16, 2020. https://grants.nih.gov/grants/guide/pa-files/PA-20-208.html

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) - The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers. Application due: May 7, 2023. https://grants.nih.gov/grants/guide/pa-files/PA-20-207.html

PAR-19-368 Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional). National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Cancer Institute ( NCI ).

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Standard application due dates apply; first available due date for this opportunity is June 5, 2020.

PAR-20-073 “National Dental Practice-Based Research Network Infrastructure Access (X01 Clinical Trial Not Allowed) National Institute of Dental and Craniofacial Research (NIDCR)

The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple clinical studies. This Funding Opportunity Announcement (FOA) is seeking applications for small developmental/exploratory, feasibility (pilot), and/or survey studies of practitioners and/or patients to be conducted in the National Dental PBRN.

Application due dates: September 1, 2021, and September 1, 2022.

PAR-19-373 Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Clinical Trials Not Allowed) and

PAR-19-384 Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Basic Experimental Studies with Humans Required)

NIH Basic Behavioral and Social Science Opportunity Network (OPPNET), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), and National Cancer Institute (NCI)

These funding opportunity announcements (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing.

Application due date: March 17, 2021

NINDS Institutional Research Training Program (T32)

https://grants.nih.gov/grants/guide/pa-files/PAR-19-211.html

The purpose of this FOA is to provide support for institutional research training programs in areas relevant to the NINDS mission. These institutional research training programs should produce well-trained neuroscientists who leave the program with the research skills and scientific knowledge to make a significant contribution to neuroscience research.

Application Due Dates: May 26, 2021, by 5:00 PM

PA-19-091 -NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) and

PA-19-092 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.”  Standard Application due dates apply

RFA-CA-20-027Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional) and

National Cancer Institute (NCI)

Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional)

Through these Funding Opportunity Announcements (FOA), the NCI intends to support research projects that improve the care and/or quality of life for childhood, and adolescent young adult (AYA) cancer survivors. Application Deadlines for both opportunities:  October 1, 2020 or July 30, 2021.

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
(PA-20-166) The National Institutes of Health (NIH) and the Center for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from underrepresented backgrounds, including those from groups that have been shown to be nationally underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project.  Administrative supplements must support work within the scope of the original project.

Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)
(PA-20-172)  The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.

Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
(RFA-RM-20-019) The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.

Notice of Special Interest (NOSI): Cannabis, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults
(NOT-DA-20-014)
National Institute on Drug Abuse

The goal of this funding is to conduct rigorous research on cannabis and potentially addictive, psychoactive prescription drug use (specifically opioids and benzodiazepine) in older adults. This program will focus on two distinct older adult populations (over the age of 50): (1) individuals with earlier use onset of cannabis and the specified drug classes who are now entering older age, or (2) individuals who initiate use of cannabis and the specified drug classes after the age of 50. Insights gained from this initiative have the potential to inform the public and health care systems regarding use of cannabis and prescription opioids and benzodiazepines in older populations.

*This funding opportunity is available through the following FOA.  Standard due dates for the FOA’s apply.

PA-19-055 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
PA-19-056 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-19-091 – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
PA-19-052: NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
PA-19-092: NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
PA-19-053: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-19-054: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)
(PA-20-173) and

Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)
(PA-20-174)
National Institutes of Health
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): Standard dates apply.

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.

Notice of Special Interest: Promoting Research on Mechanisms of Pathogenesis and Pathophysiology of Atypical Femoral Fracture (AFF) and Osteonecrosis of the Jaw (ONJ)
(NOT-AR-21-006)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute on Aging
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health

Release Date: April 15, 2020
First Available Due Date: June 05, 2020

Related Opportunities

  • PA-19-056: NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-19-053: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)

(RFA-MH-20-525)

National Institute of Mental Health

Application Receipt Date(s): June 20, 2021; June 20, 2022 No late applications will be accepted for this Funding Opportunity Announcement

Maximizing Investigators Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)

(PAR-20-117)

National Institute of General Medical Sciences

Application Receipt Date(s): October 2, 2020; October 4, 2021; October 3, 2022

Maximizing Investigators Research Award (MIRA) (R35 - Clinical Trial Optional)

https://grants.nih.gov/grants/guide/pa-files/PAR-19-367.html

(PAR-19-367)

National Institute of General Medical Sciences

Application Receipt Date(s):  January 19, 2021; May 17, 2021; January 18, 2022, May 17, 2022

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)

(PAR-20-118)

National Institute of Mental Health

National Institute on Alcohol Abuse and Alcoholism

National Institute on Drug Abuse

Application Receipt Date(s): November 25, 2020; March 25, 2021; July 26, 2021; November 26, 2021; March 25, 2022  

NIH Center Opportunities:

Intellectual and Developmental Disabilities Reserch Centers [IDDRC] FY 2021 (P50 Clinical Trial Optional) (RFA-HD-21-009) Eunice Kennedy Shriver National Institute of Child Health and Human Development Application Receipt Date(s): August 14, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

P50 Specialized Center: NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)

Application Deadlines:  September 25, 2020; September 25, 2021, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDA’s mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields.

Research Forrest